Drugs News and Research

RSS

Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.

25 Dec 2014

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

25 Dec 2014

Researchers identify key events that prompt cancer cells to develop resistance to lethal therapies

A team of researchers led by Duke Cancer Institute has identified key events that prompt certain cancer cells to develop resistance to otherwise lethal therapies.

24 Dec 2014

Intriguing small molecule directs activity of key ‘clock proteins’

In research published in Nature Communications, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports intriguing findings about a small molecule that directs the activity of key "clock proteins," offering the potential to manage circadian rhythm and treat problems that are associated with its dysfunction, like sleep and anxiety disorders.

24 Dec 2014

Patent recognizes peptide that reduces tissue damage

A Kansas State University research team has received a patent for its use of a peptide that has been shown to prevent or reduce damage to intestinal tissue.

24 Dec 2014

Cancer could be broken down by its evolving defense mechanism

Turning the tables, Katherine Borden at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) has evoked Star Trek's Borg in her fight against the disease.

24 Dec 2014

Whole-genome sequencing can identify patients' risk for hereditary cancer

UT Southwestern Medical Center cancer researchers have demonstrated that whole-genome sequencing can be used to identify patients' risk for hereditary cancer, which can potentially lead to improvements in cancer prevention, diagnosis, and care.

24 Dec 2014

PTC begins rolling NDA submission for Translarna to treat nmDMD

PTC Therapeutics, Inc. today announced that it has commenced a rolling submission of a New Drug Application to the United States Food and Drug Administration for Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).

23 Dec 2014

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

AbbVie receives Health Canada approval for HOLKIRA PAK (ombitasvir/paritaprevir/ritonavir film-coated tablets; dasabuvir film-coated tablets), an all-oral, short-course (12 weeks for the majority of patients), interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with cirrhosis.

23 Dec 2014

Endogenous retroviruses play critical role in body's immune defense against bacterial, viral pathogens

Retroviruses are best known for causing contagious scourges such as AIDS, or more sporadically, cancer.

23 Dec 2014

Medical researchers at Saint Louis University bring hope to those in pain and sickness

This year, Saint Louis University medical researchers advanced their fields, contributing to human knowledge and bringing hope to those in pain and sickness.

23 Dec 2014

Treatment for stroke: Intra-arterial treatment more effective than standard medical care for clot removal

Study results released today in The New England Journal of Medicine gave the world of stroke care more evidence that physicians are winning the battle against this debilitating disease, which affects as many as one in six people.

23 Dec 2014

Higher doses of vancomycin linked to increased risk of kidney damage in children, shows study

Results of a small Johns Hopkins Children’s Center study show that hospitalized children given high-dose IV infusions of the antibiotic vancomycin to treat drug-resistant bacterial infections face an increased risk for kidney damage — an often reversible but sometimes serious complication.

23 Dec 2014

Researchers devise new technique to understand how neutrophils move in bodily tissues

Neutrophils, a type of white blood cell, are the immune system's all-terrain vehicles. The cells are recruited to fight infections or injury in any tissue or organ in the body despite differences in the cellular and biochemical composition.

22 Dec 2014

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

22 Dec 2014

Researchers identify new genetic anomalies in smoking-related lung cancers

Developing effective treatments for lung cancer has been challenging, in part because so many genetic mutations play a role in the disease.

22 Dec 2014

Ganciclovir drug resistance may occur more frequently in cystic fibrosis patients

A drug called ganciclovir is given to lung transplant patients to protect against a life-threatening virus that is common after transplantation.

22 Dec 2014

Prostaglandin analogue eye drops reduce risk of vision loss in OAG patients

Prostaglandin analogue eye drops, the most commonly prescribed treatment for glaucoma, can greatly reduce risk of vision loss in people with open angle glaucoma (OAG), one of the leading causes of blindness, according to the first placebo-controlled trial to assess their vision-preserving effect published in The Lancet.

22 Dec 2014

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis.

21 Dec 2014

Researchers say that misfiring of the brain's control system may underpin compulsions in OCD

Misfiring of the brain's control system might underpin compulsions in obsessive-compulsive disorder (OCD), according to researchers at the University of Cambridge, writing in the American Journal of Psychiatry.

19 Dec 2014

Drugs News and Research

Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Researchers identify key events that prompt cancer cells to develop resistance to lethal therapies

Intriguing small molecule directs activity of key ‘clock proteins’

Patent recognizes peptide that reduces tissue damage

Cancer could be broken down by its evolving defense mechanism

Whole-genome sequencing can identify patients' risk for hereditary cancer

PTC begins rolling NDA submission for Translarna to treat nmDMD

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Endogenous retroviruses play critical role in body's immune defense against bacterial, viral pathogens

Medical researchers at Saint Louis University bring hope to those in pain and sickness

Treatment for stroke: Intra-arterial treatment more effective than standard medical care for clot removal

Higher doses of vancomycin linked to increased risk of kidney damage in children, shows study

Researchers devise new technique to understand how neutrophils move in bodily tissues

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Researchers identify new genetic anomalies in smoking-related lung cancers

Ganciclovir drug resistance may occur more frequently in cystic fibrosis patients

Prostaglandin analogue eye drops reduce risk of vision loss in OAG patients

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

Researchers say that misfiring of the brain's control system may underpin compulsions in OCD

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News